Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's what you need to know.

Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 demonstrate at least 10% weight loss compared with 4% for placebo. The trial is conducted in 28 days. And those with the highest dose of 100 mg lost an average of 8.2% of body weight.

Viking Therapeutics highlights VK2735's promising weight loss data at ObesityWeek 2024, with up to 14.7% reduction and improved prediabetic outcomes.

(Reuters) -Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce body weight with mild side effects in a small trial, data that analysts said compared favorably to some rivals in development.

Viking Therapeutics reported promising early results for its experimental obesity pill, with increased weight loss at higher doses. Viking stock jumped early Monday, but came well off premarket highs.